Skip to content

Study · Non-randomized trial · n = 16 · 1991

2 results

Perfluoroctylbromide as a gastrointestinal contrast agent for MR imaging: use with and without glucagon.

Brown JJ, Duncan JR, Heiken JP, Balfe DM, Corr AP, Mirowitz SA, Eilenberg SS, Lee JK

Radiology1 Nov 1991Cited by 39 (Europe PMC)

PMID1924788 (opens in a new tab)DOI10.1148/radiology.181.2.1924788 (opens in a new tab)PepBankPUB-01924788
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In healthy volunteers, glucagon significantly improved bowel-wall visualization on post-PFOB MR studies, P less than .001.

    In plain wordsIn healthy volunteers, glucagon improved bowel-wall visibility compared with imaging before glucagon.

    Peptide
    Glucagon
    Outcome
    IncreaseBowel-wall visualization
    Study

    n = 16

    Comparator
    Post-PFOB imaging before glucagon
    Outcome group
    Imaging Quality · Gastrointestinal
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    p-value
    < 0.001 p
    Bowel-wall visualization clarity after glucagon, post-PFOB MR

    Source sentences

    Summary
    Subcutaneous administration of glucagon significantly (P less than .001) increased the clarity of bowel-wall visualization on post-PFOB MR studies.
    1 context sentence
    Summary · context
    The healthy volunteers each underwent two sets of post-PFOB MR examinations, one before and one after glucagon administration.
  2. 02HumanNon-randomized trialEfficacy outcome

    In healthy volunteers, phase-encoding artifact severity did not change substantially after glucagon administration.

    In plain wordsIn healthy volunteers, glucagon did not substantially change imaging artifacts compared with imaging before glucagon.

    Peptide
    Glucagon
    Outcome
    No significant changePhase-encoding artifacts
    Study

    n = 16

    Comparator
    Post-PFOB imaging before glucagon
    Outcome group
    Imaging Quality · Gastrointestinal
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The severity of phase-encoding artifacts did not change substantially after administration of PFOB or glucagon.
    1 context sentence
    Summary · context
    The healthy volunteers each underwent two sets of post-PFOB MR examinations, one before and one after glucagon administration.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.